Action of tacrine on muscarinic receptors in rat intestinal smooth muscle.
暂无分享,去创建一个
[1] L. Parnetti,et al. Radioligand binding assay of M1–M5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes , 1999, Journal of Neuroimmunology.
[2] Ş. Oktay,et al. Subtypes of muscarinic receptors in rat duodenum: a comparison with rabbit vas deferens, rat atria, guinea-pig ileum and gallbladder by using imperialine. , 1999, General pharmacology.
[3] J. Bizot,et al. Pharmacological profile of CEB-1957 and atropine toward brain muscarinic receptors and comparative study of their efficacy against sarin poisoning. , 1998, Toxicology and applied pharmacology.
[4] R. Levin,et al. Cholinergic Modulation of Electrogenic Ion Transport in Different Regions of the Rat Small Intestine , 1997, The Journal of pharmacy and pharmacology.
[5] S. Ito,et al. Tacrine inhibits nicotinic secretory and current responses in adrenal chromaffin cells. , 1997, European Journal of Pharmacology.
[6] A. Nordberg,et al. Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors , 1996, Brain Research.
[7] R. Eglen,et al. Selective muscarinic receptor agonists and antagonists. , 1996, Pharmacology & toxicology.
[8] R. Eglen,et al. Muscarinic acetylcholine receptor subtypes in smooth muscle. , 1994, Trends in pharmacological sciences.
[9] S. E. Freeman,et al. Tacrine: A pharmacological review , 1991, Progress in Neurobiology.
[10] R. Gross,et al. Tetrahydroaminoacridine (THA) reduces voltage-dependent calcium currents in rat sensory neurons , 1991, Neuroscience Letters.
[11] R. N. Brogden,et al. Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease. , 1991, Drugs.
[12] A. Hunter,et al. The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro , 1989, British journal of pharmacology.
[13] D. Mash,et al. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. , 1989, The Journal of pharmacology and experimental therapeutics.
[14] B. Winblad,et al. Effects of THA on ionic currents in myelinated axons of Xenopus laevis. , 1989, European journal of pharmacology.
[15] S. E. Freeman,et al. Blockade of a cardiac K+ channel by tacrine: interactions with muscarinic and adenosine receptors. , 1988, European journal of pharmacology.
[16] C. Schauf,et al. Tetrahydroaminoacridine blocks potassium channels and inhibits sodium inactivation in Myxicola. , 1987, The Journal of pharmacology and experimental therapeutics.
[17] W. Osterrieder. 9‐Amino‐1,2,3,4‐tetrahydroacridine (THA) is a potent blocker of cardiac potassium channels , 1987, British journal of pharmacology.
[18] M. Rogawski. Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons. , 1987, European journal of pharmacology.
[19] J. C. Lodder,et al. 9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current. , 1987, European journal of pharmacology.
[20] A. Kling,et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.
[21] N. Birdsall,et al. Muscarinic receptor subtypes. , 1990, Annual review of pharmacology and toxicology.